Matthew W. Foehr, President and CEO of OmniAb, Inc. (NASDAQ:OABI), a biotechnology company currently valued at $486 million, recently sold shares of the company's stock, according to a recent SEC filing. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 4.62x. On December 9, 2024, Foehr sold 13,634 shares at a weighted average price of $4.13, totaling approximately $56,308. This transaction was part of a mandatory sale to cover tax obligations related to the vesting of restricted stock units.
Earlier, on December 7, 2024, Foehr acquired 26,555 shares through the vesting of restricted stock units. These shares were added to his direct holdings, which now total 3,714,447 shares following the transactions. The acquisition of these shares was part of a scheduled vesting plan that began in December 2023.
In other recent news, biotechnology firm OmniAb reported its Q3 2024 financial results, revealing a decrease in total revenue to $4.2 million from $5.5 million in the same quarter of the previous year. However, the company maintained a consistent net loss of $16.4 million. The reduction in revenue was mainly due to lower milestone and ion channel service revenue. Despite this, OmniAb finished the quarter with a robust cash position of $59.4 million, with an anticipated year-end cash balance between $50 million and $60 million.
OmniAb's R&D and G&A expenses have decreased, and the company has announced three new platform license agreements and an expanded partnership with Syngenta. The company is also preparing for the launch of its OmniHub platform. These recent developments indicate OmniAb's strategic approach to navigating industry challenges and its focus on growth opportunities. The company remains optimistic about its financial position entering 2025 and anticipates certain development milestones in Q4 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.